TOP > 外国特許検索 > ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED

ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED

外国特許コード F170009079
整理番号 (S2015-2066-N0)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP078339
国際公開番号 WO 2017057308
国際出願日 平成28年9月27日(2016.9.27)
国際公開日 平成29年4月6日(2017.4.6)
優先権データ
  • 特願2015-190401 (2015.9.28) JP
発明の名称 (英語) ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED
発明の概要(英語) Provided is an anti-REIC antibody with which it is possible to specifically recognize a cancer-related protein REIC/Dkk-3 and to monitor the results of a cancer treatment in which a REIC/Dkk-3 gene or the REIC/Dkk-3 protein is used as a medicine. Also provided is a method for diagnosis in which said antibody is used. A method for detecting cancer in which: the concentration of REIC/Dkk-3 protein in a biological sample collected from a subject is measured using a first antibody, or a functional fragment thereof, that specifically recognizes a REIC/Dkk-3 protein produced by normal cells and having an active structure, but that does not bind REIC/Dkk-3 protein present in large quantities in the blood of a cancer patient without recognizing said REIC/Dkk-3 protein or has low reactivity with REIC/Dkk-3 protein present in large quantities in the blood of a cancer patient; and, when the concentration of REIC/Dkk-3 protein in the biological sample from the subject is lower than the concentration of REIC/Dkk-3 protein in a biological sample from a normal individual, an assessment is made that the subject is affected by precancer or a neoplastic disorder.
特許請求の範囲(英語) [claim1]
1. The normal cell produces possesses the active structure which the REIC/Dkk-3 protein which it is recognized uniquely, but exists mainly in the cancer patient blood and you do not recognize the REIC/Dkk-3 protein which you do not connect, or, or exists mainly in the cancer patient blood for the REIC/Dkk-3 protein which the reactivity is low 1st the antibody or making use of the functional fragment, was picked from the suffering *** body the REIC/Dkk-3 protein density in the organism sample which than REIC/Dkk-3 protein density in the organism sample of the normal person, measure density of the REIC/Dkk-3 protein in the organism sample of the suffering *** body you are lower when, the said suffering *** body the front cancer or tumor characteristicIt judges, that you have contracted a disease in the disease, method of detection of the cancer.
[claim2]
2. Furthermore, the normal cell produces possesses the active structure which the REIC/Dkk-3 protein and exists mainly in the cancer patient blood the REIC/Dkk-3 protein which it is recognized uniquely 2nd the antibody or making use of the functional fragment, was picked from the suffering *** body, it measures the REIC/Dkk-3 protein density in the organism sample which 2nd the antibody or making use of that functional fragment, can for the measurable quantity which 1st the antibody or making use of that functional fragment can, the ratio of the measurable quantity which calculates the said ratio making use of the organism sample of the normal person, can it is lower than the ratio which when, the said suffering *** body the front cancerOr it judges, that you have contracted a disease in the tumor characteristic disease, method of detection of the cancer of claim 1 statement.
[claim3]
3. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect or or it is the antibody where the 1st antibody where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low recognizes the N terminal domain of the REIC/Dkk-3 protein uniquely, in claim 1 or 2 method of detection of the cancer of statement.
[claim4]
4. It is the antibody where the 2nd antibody which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquely recognizes the Cystein-rich domain of the REIC/Dkk-3 protein, in claim 2 or 3 method of detection of the cancer of statement.
[claim5]
5. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect or or it is the N-1 antibody which is the monoclonal antibody which recognizes the N terminal domain of the REIC/Dkk-3 protein which the hybridoma where the 1st antibody where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low is internationally deposited with trust number NITE BP-02103 produces, the 2nd antibody which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquelyIt is the Cys-3 antibody which is the monoclonal antibody which recognizes the Cystein-rich domain of the REIC/Dkk-3 protein which the hybridoma which with trust number NITE BP-02104 is internationally deposited produces, either of the claim 1-4 in 1 sections method of detection of the cancer of statement.
[claim6]
6. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect, or you measure the REIC/Dkk-3 protein density in the organism sample which was picked time-dependant from the cancer patient who receives cancer remedy making use of the 1st antibody or the functional fragment where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low, you decide, that when density of the REIC/Dkk-3 protein rose, there was cancer remedy action or an effect monitoring method of cancer remedy.
[claim7]
7. Furthermore, it measures the REIC/Dkk-3 protein density in the organism sample which was picked time-dependant from the suffering *** body making use of the 2nd antibody or the functional fragment which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquely, it calculates the ratio of the measurable quantity which can making use of the 1st antibody for the measurable quantity which can making use of the 2nd antibody it decides, that when the said ratio rose, there was cancer remedy action or an effect monitoring method of claim 6 statement.
[claim8]
8. The organism sample which was picked time-dependant, before the cancer remedying, during cancer remedying and after the cancer remedying includes the organism sample which was picked, in claim 6 or 7 monitoring method of statement.
[claim9]
9. Cancer remedy the REIC/Dkk-3 gene and the REIC/Dkk-3 fragmentary gene, is the remedy which uses the REIC/Dkk-3 protein or REIC/Dkk-3 fragmentary peptide, either of the claim 6-8 in 1 sections monitoring method of statement.
[claim10]
10. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect or or it is the antibody where the 1st antibody where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low recognizes the N terminal domain of the REIC/Dkk-3 protein uniquely, either of the claim 6-9 in 1 sections monitoring method of statement.
[claim11]
11. It is the antibody where the 2nd antibody which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquely recognizes the Cystein-rich domain of the REIC/Dkk-3 protein, either of the claim 7-10 in 1 sections monitoring method of statement.
[claim12]
12. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect or or it is the N-1 antibody which is the monoclonal antibody which recognizes the N terminal domain of the REIC/Dkk-3 protein which the hybridoma where the 1st antibody where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low is internationally deposited with trust number NITE BP-02103 produces, the 2nd antibody which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquelyIt is the Cys-3 antibody which is the monoclonal antibody which recognizes the Cystein-rich domain of the REIC/Dkk-3 protein which the hybridoma which with trust number NITE BP-02104 is internationally deposited produces, either of the claim 6-11 in 1 sections monitoring method of statement.
[claim13]
13. The antibody which recognizes C terminal domain of the antibody, or the REIC/Dkk-3 protein which recognize the Cystein-rich domain of the antibody and the REIC/Dkk-3 protein which either of the claim 1-5 in 1 sections method of detection of the cancer of statement, or either of the claim 6-12 you use for the monitoring method of statement in 1 sections, recognize the N terminal domain of the REIC/Dkk-3 protein, or those functional fragments.
[claim14]
14. The REIC/Dkk-3 protein which possesses the active structure which the normal cell produces is recognized uniquely, the hybridoma where, but you do not recognize the REIC/Dkk-3 protein which exists mainly in the cancer patient blood and do not connect, or produces the N-1 antibody where the reactivity for the REIC/Dkk-3 protein which exists mainly in the cancer patient blood is low, with trust number NITE BP-02103 is internationally deposited.
[claim15]
15. The N-1 antibody or the functional fragment which is the monoclonal antibody which the hybridoma of statement produces in claim 14.
[claim16]
16. The hybridoma which produces the Cys-3 antibody which recognizes the REIC/Dkk-3 protein which possesses the active structure which the normal cell produces and the REIC/Dkk-3 protein which exists mainly in the cancer patient blood uniquely, with trust number NITE BP-02104 is internationally deposited.
[claim17]
17. The Cys-3 antibody or the functional fragment which is the monoclonal antibody which the hybridoma of statement produces in claim 16.
[claim18]
18. The antibody which recognizes C terminal domain of the antibody or the REIC/Dkk-3 protein which recognize the Cystein-rich domain of the antibody and the REIC/Dkk-3 protein which recognize the N terminal domain of the REIC/Dkk-3 protein of statement in claim 13 is included, either of the claim 2-5 in 1 sections method of detection of the cancer of statement, or either of the claim 7-12 the inspection kit in order to use for the monitoring method of statement in 1 sections.
[claim19]
19. The Cys-3 antibody of statement is included in the N-1 antibody and claim 17 of statement in claim 15, either of the claim 2-5 in 1 sections method of detection of the cancer of statement, or either of the claim 7-12 the inspection kit in order to use for the monitoring method of statement in 1 sections.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OKAYAMA UNIVERSITY
  • MOMOTARO-GENE INC.
  • 発明者(英語)
  • KUMON HIROMI
  • KINOSHITA RIE
  • FUTAMI JUNICHIRO
国際特許分類(IPC)
指定国 (WO201757308)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close